<DOC>
	<DOC>NCT02766348</DOC>
	<brief_summary>Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.</brief_summary>
	<brief_title>Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients</brief_title>
	<detailed_description>60 patients with stage III-IV NSCLC will be randomly divided into group A (receive DC-CTL treatment with chemotherapy) or group B (Just receive chemotherapy), and the randomize ratio will be 1:1, patients in group A will receive 3 cycles of DC-CTL treatment (every 1 months) and 4 cycles of chemotherapy (every 2 weeks). Patients in group B will receive only 4 cycles chemotherapy(every 2 weeks).</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>The patient who have signed the informed consent; Histologically confirmed with NSCLC at stage IIIIV Expected survival time is more than 2 month; Eastern Cooperative Oncology Group(ECOG) performance status was 02 Hemoglobin &lt;8.0 g/dL, White blood cell &lt;3 x 10^9/L; Platelet count &lt;75 x 10^9/L; alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea nitrogen(BUN) and Creatinine(CR) more than normal limits on 3.0 times; Known or suspected allergy to the investigational agent or any agent given in association with this trial; Pregnant or lactating patients; Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection; Patients who are suffering from serious autoimmune disease; Patients who had used long time or are using immunosuppressant; Patients who had active infection; Patients who are suffering from serious organ dysfunction; Patients who are suffering from other cancer; Other situations that the researchers considered unsuitable for this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DC-CTL, NSCLC</keyword>
</DOC>